JP2009542608A5 - - Google Patents

Info

Publication number
JP2009542608A5
JP2009542608A5 JP2009517403A JP2009517403A JP2009542608A5 JP 2009542608 A5 JP2009542608 A5 JP 2009542608A5 JP 2009517403 A JP2009517403 A JP 2009517403A JP 2009517403 A JP2009517403 A JP 2009517403A JP 2009542608 A5 JP2009542608 A5 JP 2009542608A5
Authority
JP
Japan
Prior art keywords
acid
compound
group
optionally
aurora
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542608A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2007/002428 external-priority patent/WO2008001101A2/en
Publication of JP2009542608A publication Critical patent/JP2009542608A/ja
Publication of JP2009542608A5 publication Critical patent/JP2009542608A5/ja
Pending legal-status Critical Current

Links

JP2009517403A 2006-06-29 2007-06-29 医薬組合せ剤 Pending JP2009542608A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80621306P 2006-06-29 2006-06-29
PCT/GB2007/002428 WO2008001101A2 (en) 2006-06-29 2007-06-29 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
JP2009542608A JP2009542608A (ja) 2009-12-03
JP2009542608A5 true JP2009542608A5 (https=) 2011-09-08

Family

ID=38698851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517403A Pending JP2009542608A (ja) 2006-06-29 2007-06-29 医薬組合せ剤

Country Status (4)

Country Link
US (1) US20110159111A1 (https=)
EP (1) EP2043635A2 (https=)
JP (1) JP2009542608A (https=)
WO (1) WO2008001101A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
MX2007008008A (es) 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
US8404718B2 (en) * 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US9839667B2 (en) * 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US8399442B2 (en) * 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
JP5523829B2 (ja) * 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
CA2724008A1 (en) 2008-01-11 2009-09-11 Glenmark Pharmaceuticals, S.A. Fused pyrimidine derivatives as trpv3 modulators
WO2009138799A1 (en) * 2008-05-14 2009-11-19 Astex Therapeutics Limited Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea
US8318928B2 (en) 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
CN102241973B (zh) * 2011-05-04 2014-06-25 宁波大学 一种具有绿色发光性能的荧光材料及其制备方法
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
CN102329610B (zh) * 2011-09-23 2013-07-10 宁波大学 一种紫色荧光材料及其制备方法
JP2015504307A (ja) * 2011-11-22 2015-02-12 インターミューン， インコーポレイテッド 特発性肺線維症を診断および治療する方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US8895611B1 (en) 2013-07-17 2014-11-25 King Fahd University Of Petroleum And Minerals Cytotoxic compounds for treating cancer
EP3313392B1 (en) * 2015-06-23 2020-09-16 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
EP3380086B1 (en) 2015-11-25 2021-10-13 IO Therapeutics, Inc. Cyp26-resistant rar-alpha selective agonists in the treatment of cancer
BR112019003722A2 (pt) 2016-08-23 2019-05-28 Eisai R&D Man Co Ltd terapias de combinação para o tratamento de carcinoma hepatocelular
EP3518931A4 (en) * 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
TN2019000087A1 (en) 2016-10-03 2020-07-15 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
TN2019000212A1 (en) 2017-02-27 2021-01-07 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
JP2020510061A (ja) * 2017-03-14 2020-04-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾロクロロフェニル化合物、組成物及びその使用方法
MX2019010981A (es) 2017-03-16 2020-09-07 Eisai R&D Man Co Ltd Terapias de combinacion para el tratamiento de cancer de mama.
EP3720559A4 (en) * 2017-12-04 2021-10-06 Actinium Pharmaceuticals, Inc. METHODS OF TREATMENT OF PATIENTS WITH MYELODYSPLASIC SYNDROMES
US11059850B2 (en) 2017-12-08 2021-07-13 Janssen Pharmaceutica Nv Spirobicyclic analogues
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
CN112022848B (zh) * 2020-08-13 2022-02-22 中南大学湘雅二医院 索拉非尼在治疗1型糖尿病中的应用
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof
CN117562907B (zh) * 2023-11-17 2025-08-22 广州医科大学 一种提升抗癌效果的可口服吉非替尼复合物及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69630214T2 (de) * 1995-03-10 2004-07-15 Berlex Laboratories, Inc., Richmond Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
EP0906279B1 (en) * 1996-05-30 2002-10-02 F. Hoffmann-La Roche Ag Pyrrole derivatives
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DK1194425T3 (da) * 1999-06-23 2005-11-21 Aventis Pharma Gmbh Substituerede benzimidazoler
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
US6989385B2 (en) * 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE10108480A1 (de) * 2001-02-22 2002-09-05 Bayer Ag Pyrazolylpyrimidine
DE10110750A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US20040242559A1 (en) * 2003-04-25 2004-12-02 Aventis Pharma S.A. Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
GB0315657D0 (en) * 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CA2532965C (en) * 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
JP3977411B2 (ja) * 2004-03-10 2007-09-19 株式会社クレハ アミン系塩基性化合物とその用途
MX2007008008A (es) * 2004-12-30 2007-11-12 Astex Therapeutics Ltd Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
EP1845975A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
DE602006017694D1 (de) * 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
US8399442B2 (en) * 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
JP5523829B2 (ja) * 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2073807A1 (en) * 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US20080132223A1 (en) * 2006-12-04 2008-06-05 Chun-Fu Lin Systems and methods for providing traffic information

Similar Documents

Publication Publication Date Title
JP2009542608A5 (https=)
JP2009542610A5 (https=)
ES2965468T3 (es) Compuestos heterocíclicos para uso en el tratamiento del cáncer
EP2678336B1 (en) Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
EP2997030B1 (en) Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
CN107108637B (zh) 三唑并嘧啶化合物及其用途
CN106170288B (zh) 药物化合物
RU2437885C2 (ru) Производные дигидропиразолопиримидинона
JP2021522275A (ja) サイクリン依存性キナーゼ阻害剤としての２−アミノ−ピリジンまたは２−アミノ−ピリミジン誘導体
CN109970708B (zh) 大麻素受体调节剂
CN107922388A (zh) 用于抑制shp2活性的化合物和组合物
CN107207531B (zh) 作为TGF-β抑制剂的稠合的咪唑衍生物
KR20230090318A (ko) 헬리오스의 피페리디닐 소분자 분해 및 사용 방법들
PT2727918T (pt) Compostos e composições como inibidores de proteína quinase
MX2014014110A (es) Pteridinas como inhibidores del receptor del factor de crecimiento de fribroblasto (fgfr).
TW200845990A (en) Heterocyclic compounds with CXCR3 antagonist activity
BR112019024114A2 (pt) Composto, e, métodos de modulação de uma resposta imune e de profilaxia ou tratamento de uma condição
TW202313048A (zh) 組合療法
JP2012518598A (ja) ピリミドピリミドインダゾール誘導体
CN112313220B (zh) Pd-l1拮抗剂化合物
KR102926889B1 (ko) Cdk8/19 저해제
WO2020198067A1 (en) Pkm2 modulators and methods for their use
EP3397632B1 (en) 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
TW202400578A (zh) 新穎的化合物及其用於抑制檢查點激酶２的用途
EP4466265A1 (en) Deoxycytidine kinase inhibitors